519 related articles for article (PubMed ID: 27288475)
1. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women.
Schütt B; Kaiser A; Schultze-Mosgau MH; Seitz C; Bell D; Koch M; Rohde B
Hum Reprod; 2016 Aug; 31(8):1703-12. PubMed ID: 27288475
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
[TBL] [Abstract][Full Text] [Related]
3. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
Diamond MP; Stewart EA; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
Hum Reprod Open; 2019; 2019(4):hoz027. PubMed ID: 31777761
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
5. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
6. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
7. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
8. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
Bradley LD; Singh SS; Simon J; Gemzell-Danielsson K; Petersdorf K; Groettrup-Wolfers E; Ren X; Zvolanek M; Seitz C
Fertil Steril; 2019 Feb; 111(2):240-248. PubMed ID: 30527839
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
10. Effect on endometrial histology and pharmacokinetics of different dose regimens of progesterone vaginal pessaries, in comparison with progesterone vaginal gel and placebo.
Duijkers IJM; Klingmann I; Prinz R; Wargenau M; Hrafnsdottir S; Magnusdottir TB; Klipping C
Hum Reprod; 2018 Nov; 33(11):2131-2140. PubMed ID: 30265306
[TBL] [Abstract][Full Text] [Related]
11. Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women.
Schütt B; Schultze-Mosgau MH; Draeger C; Chang X; Löwen S; Kaiser A; Rohde B
J Clin Pharmacol; 2018 Feb; 58(2):228-239. PubMed ID: 28940451
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids.
Seitz C; Bumbuliene Ž; Costa AR; Heikinheimo O; Heweker A; Hudeček R; Jacquemyn Y; Melis GB; Parashar P; Rechberger T; Sánchez AC; van Aken B; Zatik J; Gemzell-Danielsson K
Contemp Clin Trials; 2017 Apr; 55():56-62. PubMed ID: 28185997
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and tolerability of progesterone vaginal pessaries versus progesterone vaginal gel for luteal phase support after in vitro fertilisation: a randomised controlled trial.
Saunders H; Khan C; D'Hooghe T; Magnúsdóttir TB; Klingmann I; Hrafnsdóttir S;
Hum Reprod; 2020 Feb; 35(2):355-363. PubMed ID: 32074281
[TBL] [Abstract][Full Text] [Related]
14. Markers of human endometrial hypoxia can be detected in vivo and ex vivo during physiological menstruation.
Reavey JJ; Walker C; Nicol M; Murray AA; Critchley HOD; Kershaw LE; Maybin JA
Hum Reprod; 2021 Mar; 36(4):941-950. PubMed ID: 33496337
[TBL] [Abstract][Full Text] [Related]
15. The effects on ovarian activity of ulipristal acetate when 'quickstarting' a combined oral contraceptive pill: a prospective, randomized, double-blind parallel-arm, placebo-controlled study.
Cameron ST; Berger C; Michie L; Klipping C; Gemzell-Danielsson K
Hum Reprod; 2015 Jul; 30(7):1566-72. PubMed ID: 25994664
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of vilaprisan in women with uterine fibroids: Data from the phase 2b randomized controlled trial ASTEROID 2.
Gemzell-Danielsson K; Heikinheimo O; Zatik J; Poka R; Rechberger T; Hudecek R; Petersdorf K; Ramirez F; Faustmann T; Groettrup-Wolfers E; Seitz C
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():7-14. PubMed ID: 32559602
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
.
Schultze-Mosgau MH; Schuett B; Hafner FT; Zollmann F; Kaiser A; Hoechel J; Rohde B
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):16-24. PubMed ID: 27841155
[TBL] [Abstract][Full Text] [Related]
18. Effect of mifepristone on the transcriptomic signature of endometrial receptivity.
von Grothusen C; Lalitkumar PG; Ruiz-Alonso M; Boggavarapu NR; Navarro R; Miravet-Valenciano J; Gemzell-Danielsson K; Simon C
Hum Reprod; 2018 Oct; 33(10):1889-1897. PubMed ID: 30137464
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study.
D'Hooghe T; Fukaya T; Osuga Y; Besuyen R; López B; Holtkamp GM; Miyazaki K; Skillern L
Hum Reprod; 2019 May; 34(5):813-823. PubMed ID: 31067329
[TBL] [Abstract][Full Text] [Related]
20. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
